Annotation Detail

Information
Associated Genes
FGFR1
Associated Variants
FGFR1 AMPLIFICATION ( ENST00000425967.8 )
FGFR1 AMPLIFICATION ( ENST00000425967.8 )
Associated Disease
bladder carcinoma
Source Database
CIViC Evidence
Description
Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. One patient with FGFR1 amplified bladder/urothelial carcinoma was treated with 125 mg and progressed rapidly in cycle 1 after 11 days of treatment.
Variant Origin
N/A
Variant Origin
N/A
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1911
Gene URL
https://civic.genome.wustl.edu/links/genes/1885
Variant URL
https://civic.genome.wustl.edu/links/variants/267
Rating
2
Evidence Type
Predictive
Disease
Bladder Carcinoma
Evidence Direction
Does Not Support
Drug
Infigratinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
27870574
Drugs
Drug NameSensitivitySupported
InfigratinibSensitivityfalse